Shore Capital is delighted to be appointed as Nominated Adviser and Sole Broker to Destiny Pharma plc (AIM: DEST). This appointment follows Shore Capital’s appointment as Joint Broker to Destiny Pharma in November 2022.
Destiny Pharma plc is a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent life threatening infections. The company has two late-stage clinical programmes and an earlier preclinical pipeline.
XF-73 Nasal is being developed from Destiny’s proprietary XF platform and is being prepared for Phase 3 studies to prevent post-surgical staphylococcal infections. Destiny Pharma is also developing a single strain, live bio-therapeutic product which is the non-toxigenic Clostridioides difficile strain M3 – for the prevention of recurring C. difficile gut infections (CDI) in conjunction with its partner Sebela Pharmaceuticals.
The company’s earlier stage pipeline is focused on other indications including two, separate dermal programmes incorporating its XF platform. Destiny Pharma is also collaborating with SporeGen on a novel SPOR-COV® innate immune system boosting nasal spray for the prevention of COVID-19 and influenza.
For further information please contact:
Shore Capital +44 (0) 20 7408 4090
Corporate Advisory: Daniel Bush / James Thomas / Lucy Bowden
For Shore Capital media enquiries, please contact:
Will Poulton: +44 (0)74 8038 3738